摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 2-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate | 642473-92-5

中文名称
——
中文别名
——
英文名称
tert-butyl 2-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate
英文别名
tert-butyl 2-[2-(ethoxymethy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate;tert-butyl N-[1-[2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]carbamate
tert-butyl 2-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate化学式
CAS
642473-92-5
化学式
C22H30N4O3
mdl
——
分子量
398.505
InChiKey
GRBNWOQDLWHDOX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    29
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    78.3
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • IMMUNE RESPONSE MODIFIER CONJUGATES
    申请人:Stoermer Doris
    公开号:US20090035323A1
    公开(公告)日:2009-02-05
    The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation.
    本发明提供了IRM共轭物,其中包括一个IRM基团和一个第二活性基团,该第二活性基团与IRM基团以共价键连接,且该共价键不依赖于紫外辐射。
  • [EN] SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES<br/>[FR] IMIDAZO-QUINOLINES A SUBSTITUTION SULFONAMIDE
    申请人:3M INNOVATIVE PROPERTIES CO
    公开号:WO2005003064A2
    公开(公告)日:2005-01-13
    Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
    含有磺酰胺官能团的咪唑喹啉和四氢咪唑喹啉化合物可用作免疫反应修饰剂。本发明的化合物和组合物可以诱导各种细胞因子的生物合成,用于治疗包括病毒性疾病和肿瘤性疾病在内的各种疾病。
  • Immunostimulatory compositions and methods of stimulating an immune response
    申请人:3M Innovative Properties Company
    公开号:US20040091491A1
    公开(公告)日:2004-05-13
    The present invention provides immunostimulatory compositions that include an immune response modifier portion paired with an antigenic portion.
    本发明提供了免疫刺激剂组合物,其包括与抗原部分配对的免疫应答调节剂部分。
  • Compositions and methods for targeted delivery of immune response modifiers
    申请人:Alkan Sefik
    公开号:US20060142202A1
    公开(公告)日:2006-06-29
    The present invention provides immunomodulatory compositions include an immune response modifier moiety coupled to a targeting moiety. In another aspect, the invention provides methods of providing targeted delivery of an IRM, generating a localized immune response, and treating a condition in a subject. Generally, the methods include administering to the subject an immunomodulatory composition that includes an immune response modifier moiety coupled to a targeting moiety that recognizes a delivery target.
    本发明提供的免疫调节组合物包括将免疫反应修饰物与靶向修饰物耦合在一起。在另一个方面,本发明提供提供定向输送IRM、生成局部免疫反应和治疗受体的方法。通常,这些方法包括向受体注射免疫调节组合物,该组合物包括将免疫反应修饰物与能识别输送目标的靶向修饰物耦合在一起。
  • Immunostimulatory Compositions
    申请人:Griesgraber George W.
    公开号:US20080193474A1
    公开(公告)日:2008-08-14
    The present invention provides immunostimulatory compositions. Generally, the immunostimulatory compositions include at least partially purified conjugates that include at least one IRM moiety covalently coupled to an antigenic peptide. In some embodiments, the immunostimulatory composition includes monomeric conjugates. In other embodiments, the immunostimulatory composition includes an aggregate of a conjugate and at least one other antigenic peptide (e.g., another conjugate and/or unconjugated peptide). The present invention also provides methods of using such immunostimulatory compositions. In some embodiments, the methods include inducing an immune response by contacting the immunostimulatory composition with an immune cell. In other embodiments, the method includes treating a condition by administering an immunostimulatory composition to a subject in an amount effective to ameliorate at least one symptom or clinical sign of the condition.
    本发明提供了免疫刺激组合物。通常,免疫刺激组合物包括至少部分纯化的共轭物,其中至少一个IRM基团与抗原肽共价耦合。在某些实施例中,免疫刺激组合物包括单体共轭物。在其他实施例中,免疫刺激组合物包括一个共轭物和至少一个其他抗原肽的聚集物(例如,另一个共轭物和/或非共轭肽)。本发明还提供了使用这种免疫刺激组合物的方法。在某些实施例中,该方法包括通过将免疫刺激组合物与免疫细胞接触来诱导免疫反应。在其他实施例中,该方法包括通过向受试者施用有效量的免疫刺激组合物来治疗疾病,以改善至少一种症状或临床表现。
查看更多